+7 (701) 759 90 19
USD 420.67 EUR 510.99
RUB 5.58 CNY 64.92
News

SK Bioscience to manufacture Novavax's coronavirus vaccine candidate

13 August 2020 22:25
Share in:
SK Bioscience to manufacture Novavax's coronavirus vaccine candidate

SEOUL. KAZINFORM SK Bioscience Co., a vaccine unit of South Korea's SK Group, said Thursday that it has secured a deal to manufacture a component of the U.S.-based biotechnology company Novavax Inc.'s experimental coronavirus vaccine.

Related news
Expo 2020 Dubai launches second edition ‘Children’s Tales From Around The World’ 11 miners rescued from east China gold mine after 14 days 'Long way' before lockdown lifted: UK health secretary

Under the agreement, SK Bioscience will manufacture the antigen component of NVX-CoV2373, Novavax's COVID-19 vaccine candidate, for supply to the global market, Yonhap reports.


«SK's accumulated vaccine R&D and production capability have been spotlighted by the world's most advanced global pharmaceutical companies, as well as the global initiatives for the COVID-19 vaccine manufacturing,» Ahn Jae-yong, CEO of SK bioscience, said in a press release.

NVX-CoV2373 was developed using Novavax's recombinant nanoparticle technology to generate a stable antigen derived from the coronavirus spike protein.

SK Bioscience will begin production of the NVX-CoV2373 antigen at its vaccine facility in the country beginning later this month.

The companies also agreed to cooperate with South Korea's Ministry of Health and Welfare to make the vaccine available in the country.



Share in:
+7
Send
Employees online
Editor
Nurmaganbetova Zhanna
Nurmaganbetova Zhanna
954-048
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048
Editor
Seilkhanov Adlet
Seilkhanov Adlet
954-048

Archive